AU2015289831B2 - Compositions and methods for targeting of the surfactant protein a receptor - Google Patents

Compositions and methods for targeting of the surfactant protein a receptor Download PDF

Info

Publication number
AU2015289831B2
AU2015289831B2 AU2015289831A AU2015289831A AU2015289831B2 AU 2015289831 B2 AU2015289831 B2 AU 2015289831B2 AU 2015289831 A AU2015289831 A AU 2015289831A AU 2015289831 A AU2015289831 A AU 2015289831A AU 2015289831 B2 AU2015289831 B2 AU 2015289831B2
Authority
AU
Australia
Prior art keywords
cells
monoclonal antibody
fragment
individual
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015289831A
Other languages
English (en)
Other versions
AU2015289831A1 (en
Inventor
Neil Christensen
Zissis CHRONEOS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Penn State Research Foundation
Original Assignee
Penn State Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penn State Research Foundation filed Critical Penn State Research Foundation
Publication of AU2015289831A1 publication Critical patent/AU2015289831A1/en
Priority to AU2020294340A priority Critical patent/AU2020294340B2/en
Application granted granted Critical
Publication of AU2015289831B2 publication Critical patent/AU2015289831B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2015289831A 2014-07-14 2015-07-14 Compositions and methods for targeting of the surfactant protein a receptor Active AU2015289831B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020294340A AU2020294340B2 (en) 2014-07-14 2020-12-30 Compositions and methods for targeting of the surfactant protein a receptor

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462024314P 2014-07-14 2014-07-14
US62/024,314 2014-07-14
US201562121830P 2015-02-27 2015-02-27
US62/121,830 2015-02-27
PCT/US2015/040304 WO2016010978A1 (en) 2014-07-14 2015-07-14 Compositions and methods for targeting of the surfactant protein a receptor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020294340A Division AU2020294340B2 (en) 2014-07-14 2020-12-30 Compositions and methods for targeting of the surfactant protein a receptor

Publications (2)

Publication Number Publication Date
AU2015289831A1 AU2015289831A1 (en) 2017-02-09
AU2015289831B2 true AU2015289831B2 (en) 2021-01-28

Family

ID=55078969

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015289831A Active AU2015289831B2 (en) 2014-07-14 2015-07-14 Compositions and methods for targeting of the surfactant protein a receptor
AU2020294340A Active AU2020294340B2 (en) 2014-07-14 2020-12-30 Compositions and methods for targeting of the surfactant protein a receptor

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020294340A Active AU2020294340B2 (en) 2014-07-14 2020-12-30 Compositions and methods for targeting of the surfactant protein a receptor

Country Status (8)

Country Link
US (1) US10077309B2 (https=)
EP (2) EP3733700A1 (https=)
JP (1) JP6495434B2 (https=)
CN (1) CN106604931B (https=)
AU (2) AU2015289831B2 (https=)
CA (2) CA3225495A1 (https=)
ES (1) ES2869909T3 (https=)
WO (1) WO2016010978A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112442126B (zh) * 2019-09-04 2022-07-29 杭州济元基因科技有限公司 一种抗人cs1抗原的单克隆抗体及其car-t细胞
EP4000597A1 (en) * 2020-11-17 2022-05-25 The Boots Company plc Tetrapeptide and compositions comprising tetrapeptides
CN116217718B (zh) * 2022-11-21 2023-08-25 浙江洪晟生物科技股份有限公司 一种猪丹毒抗体检测试剂盒及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE921342A1 (en) * 1991-04-26 1992-11-04 Surface Active Ltd Novel antibodies, and methods for their use
EP1649038B1 (en) 2003-06-26 2014-07-02 Litron Laboratories Ltd. Method for the enumeration of micronucleated erythrocyte populations while distinguishing platelets and/or platelet-associated aggregates
US8691730B2 (en) * 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8748113B2 (en) 2007-11-15 2014-06-10 The Johns Hopkins University Methods for detecting and monitoring circulating cancer stem cells
WO2010010467A2 (en) * 2008-07-25 2010-01-28 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
CN104936977B (zh) 2012-10-24 2019-10-08 开普敦大学 微管修饰化合物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
K. MORI ET AL, "Genome Structure and Differential Expression of Two Isoforms of a Novel PDZ-Containing Myosin (MysPDZ) (Myo18A)", JOURNAL OF BIOCHEMISTRY, GB, (2003-04-01), vol. 133, no. 4, pages 405 - 413 *
MORI K ET AL, "Subcellular localization and dynamics of MysPDZ (Myo18A) in live mammalian cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICAT, ELSEVIER, AMSTERDAM, NL, (2005-01-14), vol. 326, no. 2, pages 491 - 498 *
SAMTEN et al., "An antibody against the surfactant protein A (SP-A)-binding domain of the SP-A receptor inhibits T cell -mediated immune responses to Mycobacterium tuberculosis", Jnl. Leukocyte Biology, (2008-07-01), v. 84, no. 1, p115-123 *
TADASHI FURUSAWA ET AL, "Isolation of a Novel PDZ-Containing Myosin from Hematopoietic Supportive Bone Marrow Stromal Cell Lines", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (2000-04-01), vol. 270, no. 1, pages 67 - 75 *
YANG LINLIN ET AL, "Targeting of the surfactant protein A receptor SP-R210(L) variant by influenza A virus in macrophages", JOURNAL OF IMMUNOLOGY; MAY 02 -06, 2014, (2014-05-01), vol. 192, no. Suppl. 1 *

Also Published As

Publication number Publication date
CA3225495A1 (en) 2016-01-21
AU2020294340B2 (en) 2024-05-02
CN106604931A (zh) 2017-04-26
ES2869909T3 (es) 2021-10-26
CA2954518A1 (en) 2016-01-21
JP6495434B2 (ja) 2019-04-03
US10077309B2 (en) 2018-09-18
EP3733700A1 (en) 2020-11-04
CN106604931B (zh) 2020-04-21
US20170158768A1 (en) 2017-06-08
AU2020294340A1 (en) 2021-02-25
WO2016010978A1 (en) 2016-01-21
EP3172230A1 (en) 2017-05-31
EP3172230A4 (en) 2018-04-18
JP2017527268A (ja) 2017-09-21
CA2954518C (en) 2024-02-20
AU2015289831A1 (en) 2017-02-09
EP3172230B1 (en) 2021-04-14

Similar Documents

Publication Publication Date Title
KR102340352B1 (ko) 섬유증의 치료를 위한 항-fam19a5 항체의 용도
JP2019089806A (ja) 多重特異性抗原結合分子およびその使用
JP7065786B2 (ja) 肝病態を治療又は予防する方法
TR201808018T4 (tr) Anti-B7-H3 antikoru.
US11274131B2 (en) IgM-mediated receptor clustering and cell modulation
AU2020294340B2 (en) Compositions and methods for targeting of the surfactant protein a receptor
KR102061352B1 (ko) 아넥신 1 항체
ES2881303T3 (es) Método para el tratamiento o prevención del accidente cerebrovascular
KR20220031738A (ko) 암 치료를 위한 항-fam19a5 항체의 용도
AU2015225867A1 (en) Methods and compositions for modifying the immune response
JPWO2016133059A1 (ja) Ｆｓｔｌ１を利用した抗がん剤・転移抑制剤およびその併用剤
US7662382B2 (en) Inducible ligand for α1β1 integrin and uses
US20160130330A1 (en) Mammalian receptors as targets for antibody and active vaccination therapy against mold infections
US20190270798A1 (en) Methods and compositions for modulaton of transforming growth factor beta-regulated functions
CA3060080C (en) Compositions and methods for treating pulmonary fibrosis
ES2851386T3 (es) Método de tratamiento de las heridas
HK1242603B (en) Method of treating or preventing stroke

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 14 JUL 2019 TO 14 APR 2020 IN WHICH TO PAY A CONTINUATION FEE HAS BEEN FILED

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY A CONTINUATION FEE HAS BEEN EXTENDED TO 14 APR 2020

FGA Letters patent sealed or granted (standard patent)